Caribou Biosciences said it is preparing to widen access to donor-derived CAR T by moving a pivotal Phase III study forward, leveraging its genome editing strategy and product optimization. The company highlighted an approach intended to deliver off-the-shelf dosing and reduce the logistical bottlenecks that slow autologous CAR T manufacturing. Caribou’s technical plan includes donor selection under age 30, plus a “high-fidelity” genome editing technology (chRDNA) designed to reduce off-target effects and support persistence. The company also said matching patient and donor HLAs from its inventory is associated with better durability of response. Caribou cited market access constraints, estimating 75% to 90% of eligible CAR T patients do not receive therapy due to rapid disease progression, manufacturing timelines, or socioeconomic and insurance barriers. The company’s strategy aims to dose patients without bespoke manufacturing and to scale to hundreds of doses per batch to lower cost of goods. For developers, the update reinforces the growing push toward universal, inventory-based CAR T programs—especially where patient logistics and time-to-treatment determine whether therapy reaches the clinic.